31 August 1998 00:00 [Source: ICB]
ChiRex has signed an exclusive licensing agreement with the Massachusetts Institute of Technology (MIT) to use MIT's metal-catalysed aromatic carbon-heteroatom bond-forming technologies (ABT) for use in the production of pharmaceutical and agrochemical intermediates. ChiRex expects the ABT technology to reduce the complexity and cost of manufacture of intermediates as well as improving purity.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Sample issue >>
My Account/Renew >>
Register for online access >>
|ICIS Top 100 Chemical Companies|
|Download the listing here >>|